

































- of lupus nephritis: a meta-analysis of randomized controlled trials. *Drugs*. 2012; 72: 1521-33.
109. Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. *Int J Antimicrob Agents*. 2007; 30: 297-308.
110. Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today's diseases? *Lancet Infect Dis*. 2003; 3: 722-7.
111. Witt M, Grunke M, Proft F, et al. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). *Lupus*. 2013; 22: 1142-9.
112. Bang SY, Lee CK, Kang YM, et al. Multi-center Retrospective Analysis of the Effectiveness and Safety of Rituximab in Korean Patients with Refractory Systemic Lupus Erythematosus. *Autoimmune Dis*. 2012: 565039.
113. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. *Arthritis Rheum*. 2010; 62: 2458-66.
114. Díaz-Lagares C, Pérez-Alvarez R, García-Hernández FJ, et al. Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. *Arthritis Res Ther*. 2011; 13: R112.
115. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. *Arthritis Rheum*. 2011; 63: 3918-30.
116. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet*. 2011; 377: 721-31.
117. Cassaniti I, Cavagna L, Calarota S, et al. Evaluation of EBV- and HCMV-Specific T Cell Responses in Systemic Lupus Erythematosus (SLE) Patients Using a Normalized Enzyme-Linked Immunospot (ELISPOT) Assay. *J Immunol Res*. 2019; 2019: 1-12.
118. Sève P, Ferry T, Koenig M, et al. Lupus-like presentation of parvovirus B19 infection. *Semin Arthritis Rheum*. 2005; 34: 642-8.
119. Castellino G, Govoni M, Trotta F. Comment on "Leishmania in SLE mimicking and exacerbation". *Clin Exp Rheumatol*. 2007; 25: 661.
120. Gómez J, Suárez A, López P, et al. Systemic Lupus Erythematosus in Asturias, Spain. *Med*. 2006; 85: 157-68.
121. Mehrotra R, Marsh D, Vonesh E, et al. Patient education and access of ESRD patients to renal replacement therapies beyond in-center hemodialysis. *Kidney Int*. 2005; 68: 378-90.
122. Zhou W, Yang C. The causes and clinical significance of fever in systemic lupus erythematosus: a retrospective study of 487 hospitalized patients. *Lupus* 2009; 18: 807-12.
123. Benzel J, Malik V, Lacey S, et al. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. *J NeuroVirol*. 2018; 24: 323-31.
124. Son C, Lee T, Bang J, et al. The relationship between anti-C-reactive protein and disease activity in patients with systemic lupus erythematosus. *Korean J Intern Med*. 2018; 33: 823-8.
125. Kapoor T, Mahadeshwar P, Hui-Yuen J, et al. Prevalence of progressive multifocal leukoencephalopathy (PML) in adults and children with systemic lupus erythematosus. *Lupus Sci Med*. 2020; 7: e000388.